Fulcrum's (FULC) experimental oral treatment for sickle cell disease demonstrates stronger fetal hemoglobin increases at 20mg dose, though researchers emphasize it's not a cure for the genetic disorder.
Wells Fargo upgrades Merck to Overweight; Truist and H.C. Wainwright initiate coverage on BeOne Medicines, MeiraGTx, MannKind, and Fulcrum with Buy ratings and promising price targets.
Fulcrum Therapeutics rises as Agios’ RISE UP trial falls short. Analysts say results reduce competition in sickle cell disease and strengthen Fulcrum’s position ahead of new PIONEER data.
